Bayer plans up to $2.2 billion pharmaceutical manufacturing campus in Ohio

A flexible manufacturing campus in New Albany

Bayer plans to invest up to $2.2 billion in a new pharmaceutical manufacturing facility in New Albany, Ohio, according to Greek business publication SBCTV. The project places additional production capacity in one of the German group’s most important markets and reflects a wider pharmaceutical industry effort to locate manufacturing closer to major centers of demand.

The plant is designed as a modular campus that will combine the production of active pharmaceutical ingredients and finished medicines. Advanced digital systems are intended to help the site adjust more quickly to new therapies and changing production requirements. The planned capabilities will support Bayer’s work in oncology, cardiovascular medicine and renal care, therapeutic areas where demand is high and product cycles are becoming shorter.

Employment and supply-chain effects

The investment is expected to create about 600 permanent jobs and 1,500 construction jobs. Beyond its direct effect on employment, the project should expand Ohio’s pharmaceutical manufacturing base and create demand for engineering, automation, quality-control and other specialist services required to commission and operate a modern drug plant.

SBCTV said Ohio’s universities, research centers, life-sciences workforce and tax incentives contributed to the location’s appeal. Access to qualified employees can reduce execution risks for a technically complex project and help a new facility reach stable operations more rapidly. No construction schedule or expected opening date was provided in the source material.

More production inside the US market

The project comes as major pharmaceutical companies seek to reduce their exposure to distant supply chains following pandemic-era disruptions and geopolitical tensions. A US manufacturing presence gives Bayer capacity closer to American patients and customers, while integrating active-ingredient and finished-product operations at one campus could improve control over production planning and supply continuity.

The investment also fits US industrial-policy efforts to increase domestic capacity for strategically important medicines. For a European company, physical production in the United States may provide some protection against future trade or regulatory barriers. The project therefore carries significance beyond its nominal capacity: it places flexible infrastructure inside the target market and allows production lines to be adapted as Bayer’s treatment portfolio changes.

Competitive implications for European manufacturers

Bayer’s plan illustrates how investment is moving toward highly digitalized plants capable of producing specialized therapies. European manufacturers focused mainly on generic medicines face a different capital and technology profile. Maintaining access to large markets may require greater spending on automation, quality systems and partnerships with multinational drugmakers.

The Ohio campus may also generate opportunities for overseas suppliers of manufacturing equipment, automation, clinical-research services and data analytics, provided they can meet pharmaceutical quality requirements and enter Bayer’s international supply chain. For governments seeking comparable investments, the competition involves more than operating costs: research links, skilled labor, dependable regulation and tax policy can all influence where advanced pharmaceutical capacity is built.